Posts tagged “Biotech & Life Science”
Cancer products firm DARA BioSciences at risk of delisting
The Nasdaq has notified DARA BioSciences that the company's stock price is too low for listing requirements. Learn what DARA's options are.
Health care software firm Axial Exchange raising $2M
Axial has developed software that enables hospitals and other health care facilities communicate in real time. Learn how the company aims to use it to improve health care.
Raleigh-based PRA International eyes public offering
Another life science services firm in the Triangle, PRA International, may follow in the footsteps of a bigger rival - Quintiles - by offering stock in order to raise capital. Just two years ago, PRA was at the center of takeover rumors in the range of $1 billion.
Syngenta unveils $72M Advanced Crop Lab in RTP
Built around 30 climate-controlled "environments" contained in all-glass greenhouses, the new 136,000 square foot facility had been under construction for nearly two years.
OxyBio gets more time to show it meets NASDAQ listing rules
The Nasdaq, which had sent Oxygen Biotherapeutics, a delisting notice in March, gives the company more time to show it meets listing requirements.
SAS pounces on 'big data' opportunities in health analytics
New SAS software cuts "big data" analysis from days, even hours, down to seconds. Learn why SAS sees big opportunity in the health care space.
New drug model? Quintiles to develop compounds with Merck Serono
Fresh off an IPO that produced $1 billion for investors and the company, Quintiles on Wednesday announced a drug development deal in which it will work with Germany-based Merck Serono. But this contract is much different from others in which Quintiles shared some of the financial risk for new drug development. WRALTechWire Insiders get the story beyond the press release.
Quintiles IPO tops $1 billion, including overallotment
Quintiles completes its IPO selling 27.2 million shares, including the overallotment sold by investors who took stakes in Quintiles when it was private. Read just how much they stand to gain from the additional sale.
Quintiles made plans to cut 400 jobs as it geared up for IPO
With its stock trading at a new high on Tuesday, Quintiles disclosed before the markets opened in a regulatory filing that it set aside $15 million to cover the costs of "restructuring" 400 workers.
The New Bull City: An in-depth series coming to WRALTechWire
From a tobacco town to a city of medicine to a technology hub - that's the saga of Durham. Beginning next week, WRALTechWire will launch a multi-day, in-depth report titled "The New Bull City" that will tell the stories behind Durham's rebirth and what's coming next.
HyperBranch Medical raising $1M; surgical sealant is in clinical trials
HyperBranch Medical Technology's surgical sealant is in clinical trials. Learn more about the sealant and its potential surgical applications.
Chapel Hill drug startup Cempra lands $70M licensing deal
Cemrpa is a long way yet from proving its new antibiotic compound will be an effective, FDA-approved drug, but the compound has already delivered the company a $10 million payday with millions more possibly to come. WRALTechWire Insiders get the details.
Time running out to save 50% on WRALTechWire Insider membership
The introductory 50-percent off deal to become an Insider at WRALTechWire expires on May 16. Sign up today for accesses to in-depth exclusive news and much more - such as up to $900 in savings on tech-related offers from our partners.
Durham drug firm Chimerix reports $9.1M quarterly loss
The company, which went public in April, reports a drop in revenue and an increase in expenses. But stock rallies 4 percent on the news.
Supreme Court unanimously backs Monsanto on crop patents
The justices unanimously upheld an $84,456 award Monsanto won in a lawsuit against an Indiana farmer who sought to circumvent the company's patents on herbicide-resistant soybean seeds.
Elan to pay $1B for a share of Theravance's royalties from GSK
Elan will receive 21 percent of the royalties earned by Theravance from GlaxoSmithKline on the four respiratory medicines, and 20 percent of that income stream will be paid to Elan shareholders as a dividend.
Billionaire Murdock on nutrition research: 'Let's make some major discoveries'
Scientific research has revealed many things but science is still keeping some secrets from David Murdock. The billionaire businessman founded and funded the David H. Murdock Research Institute to search for answers. And now he's putting up $50 million more in his continuing quest.
WRALTechWire invites readers to submit news, analysis
WRALTechWire is expanding its content lineup, and we want you to participate. We are looking for news and analysis about all things tech and life science from people who know their business.


























